Loading
D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
D-0502 is a small-molecule drug developed by InventisBio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial. ClinicalTrials.gov describes the intervention as: * Dosage form: Tablet * Administration route: Oral, once a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT06954961, plans to enrol 640 participants with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial.
1.D-0502 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"D-0502" OR ABSTRACT:"D-0502") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about D-0502, not a curated reading list.
Shares InventisBio and the tag pipeline.
Shares InventisBio and the tag pipeline.
Shares InventisBio and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.